secwatch.observer — SEC 8-K summary
======================================

Issuer:     VivoSim Labs, INC. (VIVS)
CIK:        0001497253
Form:       8-K
Filed at:   2024-11-22T23:59:59+00:00
Accession:  0000950170-24-129965
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organovo shareholders approve reverse stock split (1:5-1:20) and 1.78M share equity plan increase
--------------------------------------------------------------------------------

- Reverse stock split authorized at ratio 1-to-5 to 1-to-20, board discretion until Nov 20, 2025; 88.64% voted for.
- 2022 Equity Incentive Plan amended to add 1,775,000 shares; 89.41% approval.
- Class I directors Alison Tjosvold Milhous and Vaidehi Joshi elected with ~92.4% and ~93.9% of votes cast, respectively.
- Rosenberg Rich Baker Berman ratified as auditor for FY ending March 2025 (89.25% approval).
- Advisory vote on named executive officer compensation passed with 92.30% of votes cast.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497253/000095017024129965/0000950170-24-129965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497253/000095017024129965/onvo-20241120.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-129965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer